| Similar Articles |
|---|
 |
The Motley Fool
June 25, 2008
Brian Orelli |
An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.   |
The Motley Fool
June 27, 2008
Brian Orelli |
Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out. |
The Motley Fool
May 12, 2008
Brian Orelli |
Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations. |
The Motley Fool
February 29, 2008
Brian Orelli |
Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006. |
The Motley Fool
March 5, 2008
Brian Orelli |
Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent. |
The Motley Fool
August 8, 2008
Rich Duprey |
Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals. |
The Motley Fool
August 29, 2008
Brian Orelli |
A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug. |
The Motley Fool
March 13, 2008
Stephen Albainy-Jenei |
Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex. |
The Motley Fool
December 17, 2007
Brian Orelli |
Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill. |
The Motley Fool
July 28, 2009
Brian Orelli |
All Growth, All the Time This generic-drug maker is no value play. |
The Motley Fool
July 26, 2007
Brian Orelli |
Barr Gets Sued, Again This is starting to be a bad habit at Barr Pharmaceutical. The drug maker has just been sued for the third time in as many weeks. The latest one is by Schering-Plough, over patent infringement of its brain cancer treatment drug. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most. |
The Motley Fool
September 15, 2008
Brian Orelli |
Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
The Motley Fool
May 15, 2008
Brian Orelli |
Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch. |
The Motley Fool
April 14, 2008
Brian Orelli |
Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal. |
The Motley Fool
July 16, 2007
Brian Orelli |
Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price. |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
The Motley Fool
February 28, 2008
Brian Lawler |
Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
The Motley Fool
December 3, 2008
Brian Orelli |
High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition. |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
July 1, 2008
Brian Orelli |
As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal. |
The Motley Fool
June 25, 2009
Brian Orelli |
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
March 29, 2011
Brian Orelli |
Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate. |
The Motley Fool
September 11, 2007
Brian Orelli |
Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix... |
The Motley Fool
June 3, 2010
Brian Orelli |
When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors. |
The Motley Fool
December 31, 2008
Brian Orelli |
Bayer's Little Lost Drug Patent The drugmaker is dusting one off and suing Abbott Labs. |
The Motley Fool
January 8, 2010
Brian Orelli |
Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Johnson & Johnson Ever Get Its Money? For investors, there are a couple of lessons here. First, perhaps more than any other, the health care sector has a lot of lawsuits. |
The Motley Fool
March 3, 2010
Brian Orelli |
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. |
The Motley Fool
January 3, 2008
Brian Orelli |
8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny. |
The Motley Fool
July 14, 2008
Brian Orelli |
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone. |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
BusinessWeek
June 24, 2010
Bliss & Decker |
Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete. |
The Motley Fool
November 26, 2008
Brian Orelli |
Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better." |
The Motley Fool
March 7, 2007
Rich Duprey |
Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug. |
The Motley Fool
September 9, 2010
Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
The Motley Fool
July 30, 2008
Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
The Motley Fool
April 25, 2011
Sean Williams |
Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing. |
The Motley Fool
July 18, 2008
Rich Duprey |
More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry. |
The Motley Fool
November 3, 2009
Brian Orelli |
Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call. |
The Motley Fool
May 29, 2009
Brian Orelli |
Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
